Paul A. Reilly

Idarucizumab for Dabigatran Reversal

Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine · 2015 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +4

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis

José M. Ferro, Jonathan M. Coutinho, Francesco Dentali et al. · JAMA Neurology · 2019 · 302 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Oral bioavailability of dabigatran etexilate (<scp>P</scp>radaxa^®) after co‐medication with verapamil in healthy subjects

Sebastian Härtter, Regina Sennewald, Gerhard Nehmiz et al. · British Journal of Clinical Pharmacology · 2012 · 161 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Paul A. Reilly, Richard A. Bernstein, Robert Dubiel et al. · Thrombosis and Haemostasis · 2015 · 154 citations

Medicine, Pharmacology, Pharmacotherapy +17

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Leonardo R. Brandão, Matteo Luciani, Lisa Bomgaars et al. · The Lancet Haematology · 2020 · 149 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +12